Author Archives: admin


Stem Cell Clinic > Articles by: admin

Global Cell Banking Outsourcing Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2024 with COVID-19 Impact – The Daily…

By Stell Cell Research

Cell Bank Preparation

Inquire Or Share Questions If Any Before The Purchase On This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/13763969

This report also splits the market by region:

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

Key Reasons to Purchase

Purchase This Report (Price 3660 USD for single user license) https://www.absolutereports.com/purchase/13763969

Detailed TOC of Global Cell Banking Outsourcing Market Growth 2019-2024

Table of Contents

Global Cell Banking Outsourcing Market Forecast 2019-2024

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Cell Banking Outsourcing Market Industry

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Cell Banking Outsourcing Forecast 2014-2024

2.1.2 Cell Banking Outsourcing Consumption CAGR by Region

2.2 Cell Banking Outsourcing Segment by Type

2.2.1 Type 1

2.2.2 Type 2

2.3 Cell Banking Outsourcing Consumption by Type

2.3.1 Global Cell Banking Outsourcing Consumption Market Share by Type (2014-2019)

2.3.2 Global Cell Banking Outsourcing Revenue and Market Share by Type (2014-2019)

2.3.3 Global Cell Banking Outsourcing Sale Price by Type (2014-2019)

2.4 Cell Banking Outsourcing Segment by Application

2.4.1 Application 1

2.4.2 Application 2

2.5 Cell Banking Outsourcing Consumption by Application

2.5.1 Global Cell Banking Outsourcing Consumption Market Share by Application (2014-2019)

2.5.2 Global Cell Banking Outsourcing Value and Market Share by Application (2014-2019)

2.5.3 Global Cell Banking Outsourcing Sale Price by Application (2014-2019)

3 Global Cell Banking Outsourcing by Players

3.1 Global Cell Banking Outsourcing Sales Market Share by Players

3.1.1 Global Cell Banking Outsourcing Sales by Players (2017-2019)

3.1.2 Global Cell Banking Outsourcing Sales Market Share by Players (2017-2019)

3.2 Global Cell Banking Outsourcing Revenue Market Share by Players

3.2.1 Global Cell Banking Outsourcing Revenue by Players (2017-2019)

3.2.2 Global Cell Banking Outsourcing Revenue Market Share by Players (2017-2019)

3.3 Global Cell Banking Outsourcing Sale Price by Players

3.4 Global Cell Banking Outsourcing Manufacturing Base Distribution, Sales Area, Product Types by Players

3.4.1 Global Cell Banking Outsourcing Manufacturing Base Distribution and Sales Area by Players

3.4.2 Players Cell Banking Outsourcing Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

And Continue

Browse Table Of Content(TOC) At https://www.absolutereports.com/TOC/13763969#TOC.

Contact Us:

Name: Ajay More

Phone: US +1424 253 0807/ UK +44 203 239 8187

Mail id: [emailprotected]

Our Other report : Global PV Metallization Aluminium Paste Market by Manufacturers, Regions, Type and Application, Forecast to 2025

Global Bulk Food Ingredients Market Research Report 2020: Size, Share, Growth, Trends and Forecast 2026

Global Head-Up Displays(Huds) Market Segmentation and Analysis by Recent Trends, Development Trends and Growth Rate by Regions to 2026

Global Structure-Mounted Noise Barrier Market 2020 Recent Study including Growth Factors, Applications, Regional Analysis, Key Players and Forecasts 2026

Facial Rejuvenation Products Market 2020 Report Presents an Overall Analysis, Development Trends, Driving Forces, Opportunities & Future Potential 2024

Our Other report : Polypropylene (PP) Synthetic Paper Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Revenue Market Forecast 2025

Beta-Phellandrene (CAS 555-10-2) Market Overview, Industry Top Manufactures, Market Size, Industry Growth Analysis & Forecast: 2026

Global Luxury Furniture Market Size, Share, Supply, Demand, Segments and Forecast 2020-2025

Global Tin-Bronze Market 2020 Growth Factors, Types and Application by Regional Geography 2026

Global Monocalcium Phosphate (MCP) Market 2020 Outlook to 2025: Top Companies in Market, Trends & Growth Factors and Details for Business Development

Global Desk and Office Cleaner Market 2020 Recent Study including Growth Factors, Applications, Regional Analysis, Key Players and Forecasts 2026

Worldwide Heat Interface Units (HIU) Market Outlook to 2025: Emerging Trends and Will Generate New Growth Opportunities Status

Global Benign Prostate Hyperplasia Drugs Market Size, Share, Supply, Demand, Segments and Forecast 2020-2025

Global Automobile Switches Market 2020 Outlook to 2025: Top Companies in Market, Trends & Growth Factors and Details for Business Development

Global Air Swept Hammer Mills Market 2020 Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2024

Global Paclitaxel Market 2020 Size, Share, Growth, Trends and Forecast 2024, Business Opportunities and Future Investments

Aerial Cables & Accessories Market Size 2020 by Consumption Volume, Average Price, Revenue, Market Share and Trend to 2026

Data Center Liquid Immersion Cooling Market 2020 Analysis Manufacturing Cost Structure, Industry Chain Structure, Raw Material and Suppliers Opportunities & Future Potential 2024

Automotive Tire Tread Sensors Market 2020 Scope, Market Classification, Research Objectives Forecasts 2024

More here:
Global Cell Banking Outsourcing Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2024 with COVID-19 Impact - The Daily...

Stem Cell Umbilical Cord Blood Market 2020 Size, Share, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans,…

By Stell Cell Research

Global Stem Cell Umbilical Cord Blood Market 2020 Industry Research Report is an inside-out and expert examination on the flow condition of the Global Stem Cell Umbilical Cord Blood industry. In addition to that, this latest investigative report sorts the global Stem Cell Umbilical Cord Blood market by end client, type, area, and top players/brands. This report further elaborates various factors affecting the market drivers and development. Stem Cell Umbilical Cord Blood market also puts forward insights into market size, crucial markers, review, as well as the most recent net edge, income, types, patterns, along with provincial figure and examination.

Get a Sample PDF of report at https://www.researchreportsworld.com/enquiry/request-sample/15605179

The global Stem Cell Umbilical Cord Blood market is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2026. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

The Global Stem Cell Umbilical Cord Blood market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Umbilical Cord Blood Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Final Report will add the analysis of the impact of COVID-19 on this industry.

Under COVID-19 Outbreak, how the Stem Cell Umbilical Cord Blood Industry will develop is also analyzed in detail in Chapter 1.7 of the report. In Chapter 2.4, we analyzed industry trends in the context of COVID-19 for Stem Cell Umbilical Cord Blood Market. In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets for Stem Cell Umbilical Cord Blood Market. In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries on Stem Cell Umbilical Cord Blood Market. In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

To Understand How COVID-19 Impact is Covered in This Report. Get Sample copy of the report at https://www.researchreportsworld.com/enquiry/request-covid19/15605179

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Umbilical Cord Blood industry.This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Umbilical Cord Blood manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

Global Stem Cell Umbilical Cord Blood Market Report 2020 provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Enquire before purchasing this report https://www.researchreportsworld.com/enquiry/pre-order-enquiry/15605179

List Of TOP KEY PLAYERS in Stem Cell Umbilical Cord Blood Market Report are

Get a Sample Copy of the Stem Cell Umbilical Cord Blood Market Report 2020

The report also focuses on global major leading industry players of Global Stem Cell Umbilical Cord Blood Market Share providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. With tables and figures helping analyse worldwide Global Stem Cell Umbilical Cord Blood Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The Global Stem Cell Umbilical Cord Blood Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Purchase this report (Price 3400 USD for single user license) https://www.researchreportsworld.com/purchase/15605179

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Some of the key questions answered in this report:

Major regions covered in the report:

Major Points from Table of Contents:

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Regulatory Scenario by Region/Country 1.4 Market Investment Scenario Strategic 1.5 Market Analysis by Type 1.5.1 Global Stem Cell Umbilical Cord Blood Market Share by Type (2020-2026) 1.5.2 Allogeneic stem cell umbilical cord blood 1.5.3 Autologous stem cell cord blood 1.6 Market by Application 1.6.1 Global Stem Cell Umbilical Cord Blood Market Share by Application (2020-2026) 1.6.2 Blood Disorders 1.6.3 Cancers 1.6.4 Immune Disorders 1.6.5 Metabolic Disorders 1.6.6 Others 1.7 Stem Cell Umbilical Cord Blood Industry Development Trends under COVID-19 Outbreak 1.7.1 Global COVID-19 Status Overview 1.7.2 Influence of COVID-19 Outbreak on Stem Cell Umbilical Cord Blood Industry Development

2. Global Market Growth Trends 2.1 Industry Trends 2.1.1 SWOT Analysis 2.1.2 Porters Five Forces Analysis 2.2 Potential Market and Growth Potential Analysis 2.3 Industry News and Policies by Regions 2.3.1 Industry News 2.3.2 Industry Policies 2.4 Industry Trends Under COVID-19

3 Value Chain of Stem Cell Umbilical Cord Blood Market 3.1 Value Chain Status 3.2 Stem Cell Umbilical Cord Blood Manufacturing Cost Structure Analysis 3.2.1 Production Process Analysis 3.2.2 Manufacturing Cost Structure of Stem Cell Umbilical Cord Blood 3.2.3 Labor Cost of Stem Cell Umbilical Cord Blood 3.2.3.1 Labor Cost of Stem Cell Umbilical Cord Blood Under COVID-19 3.3 Sales and Marketing Model Analysis 3.4 Downstream Major Customer Analysis (by Region) 3.5 Value Chain Status Under COVID-19

4 Players Profiles 4.1 StemOne Biologicals 4.1.1 StemOne Biologicals Basic Information 4.1.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.1.3 StemOne Biologicals Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.1.4 StemOne Biologicals Business Overview 4.2 Cordlife 4.2.1 Cordlife Basic Information 4.2.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.2.3 Cordlife Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.2.4 Cordlife Business Overview 4.3 Cryosite 4.3.1 Cryosite Basic Information 4.3.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.3.3 Cryosite Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.3.4 Cryosite Business Overview 4.4 CBR (Cord Blood Registry) 4.4.1 CBR (Cord Blood Registry) Basic Information 4.4.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.4.3 CBR (Cord Blood Registry) Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.4.4 CBR (Cord Blood Registry) Business Overview 4.5 ViaCord 4.5.1 ViaCord Basic Information 4.5.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.5.3 ViaCord Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.5.4 ViaCord Business Overview 4.6 Cryolife 4.6.1 Cryolife Basic Information 4.6.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.6.3 Cryolife Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.6.4 Cryolife Business Overview 4.7 Cell Care 4.7.1 Cell Care Basic Information 4.7.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.7.3 Cell Care Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.7.4 Cell Care Business Overview 4.8 Cryo-Cell 4.8.1 Cryo-Cell Basic Information 4.8.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.8.3 Cryo-Cell Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.8.4 Cryo-Cell Business Overview 4.9 Stemcyte Inc 4.9.1 Stemcyte Inc Basic Information 4.9.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.9.3 Stemcyte Inc Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.9.4 Stemcyte Inc Business Overview 4.10 Cells for Life 4.10.1 Cells for Life Basic Information 4.10.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.10.3 Cells for Life Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.10.4 Cells for Life Business Overview 4.11 Healthbanks Biotech 4.11.1 Healthbanks Biotech Basic Information 4.11.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.11.3 Healthbanks Biotech Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.11.4 Healthbanks Biotech Business Overview 4.12 CELLTREE(CELLTREE) 4.12.1 CELLTREE(CELLTREE) Basic Information 4.12.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.12.3 CELLTREE(CELLTREE) Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.12.4 CELLTREE(CELLTREE) Business Overview 4.13 LifeCell 4.13.1 LifeCell Basic Information 4.13.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.13.3 LifeCell Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.13.4 LifeCell Business Overview 4.14 Smart Cells 4.14.1 Smart Cells Basic Information 4.14.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.14.3 Smart Cells Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.14.4 Smart Cells Business Overview 4.15 Stemlife 4.15.1 Stemlife Basic Information 4.15.2 Stem Cell Umbilical Cord Blood Product Profiles, Application and Specification 4.15.3 Stemlife Stem Cell Umbilical Cord Blood Market Performance (2015-2020) 4.15.4 Stemlife Business Overview

5 Global Stem Cell Umbilical Cord Blood Market Analysis by Regions 5.1 Global Stem Cell Umbilical Cord Blood Sales, Revenue and Market Share by Regions 5.1.1 Global Stem Cell Umbilical Cord Blood Sales by Regions (2015-2020) 5.1.2 Global Stem Cell Umbilical Cord Blood Revenue by Regions (2015-2020) 5.2 North America Stem Cell Umbilical Cord Blood Sales and Growth Rate (2015-2020) 5.3 Europe Stem Cell Umbilical Cord Blood Sales and Growth Rate (2015-2020) 5.4 Asia-Pacific Stem Cell Umbilical Cord Blood Sales and Growth Rate (2015-2020) 5.5 Middle East and Africa Stem Cell Umbilical Cord Blood Sales and Growth Rate (2015-2020) 5.6 South America Stem Cell Umbilical Cord Blood Sales and Growth Rate (2015-2020)

Continued

Browse complete table of contents at https://www.researchreportsworld.com/TOC/15605179

About Us:

Research Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs. At Research Reports World, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:

Name: Ajay More

Email: [emailprotected]

Phone: US+1424 253 0807/UK+44 203 239 8187

Other Reports Here:

Solar Air Conditioning Market 2020 Covid-19 Impact Analysis on Global Industry Size, Share, Analysis, Development, Revenue, Future Growth, Business Prospects and Forecast to 2026 Research Reports World

Effervescent Packaging Market 2020 Global impact of COVID-19 on Industry Share, Size, Trends, Sales Revenue, Industry Growth, Development Status, Top Leaders, Future Plans and Opportunity Assessment 2026

Direct Digital Controllers Market 2020 Global Industry Future Trends, Growth, Strategies, Size, Share, Segmentation, Indepth Analysis Research Report by Foresight to 2026 | COVID-19 Impact on Industry

Prothioconazole Market Research Reports 2020 Global COVID-19 Impact on Industry Size, Share, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by Research Reports World

Soil Penetrant Market Share, Size, 2020 Covid-19 Impact Analysis on Industry Growth by Global Major Companies Profile, Competitive Landscape and Key Regions 2026 Research Reports World

Cosmetic Bottle Packaging Market 2020 impact of COVID-19 onShare, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026

Signalling and Data Cables Market 2020 Global Industry Size, Revenue Growth Development, Business Opportunities, Future Trends, Top Key Players, Covid-19 Impact Analysis on Market Share and Global Analysis by Forecast to 2026

Asbestos Hat Market Share, Growth 2020 Global Industry Size, Future Trends, Growth Key Factors, Demand, Sales and Income, Manufacture Players, Application, Scope, and Opportunities Analysis by Outlook 2025 | COVID-19 Impact on Industry

Cardiac Pacing Market Growth 2020 Global Industry Size, Analysis, Share, Trends, Market Demand, Growth, Opportunities and Covid-19 Impact Analysis on Forecast 2026

3D Fabrics Market 2020 Global Market Size, Analysis, Share, Research, impact of COVID-19 onBusiness Growth and Forecast to 2026 Research Reports World

Read the original post:
Stem Cell Umbilical Cord Blood Market 2020 Size, Share, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans,...

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is Expected to Reach a Value of Approximately US$ 450.5 Mn by the End of 2026 – Science…

By Stell Cell Research

Transparency Market Research (TMR) has published a new report titled Platelet Rich Plasma & Stem Cell Alopecia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, the global platelet rich plasma & stem cell alopecia treatment market was valued at approximately US$ 250Mn in 2017. The market is anticipated to reach a value of US$ 450.5 Mn by 2026, expanding at a higher single digit CAGR during the forecast period. Rise in awareness about platelet rich plasma & stem cell alopecia treatment and increase in funding for alopecia treatment research and stem cell research are expected to augment the global market from 2018 to 2026. The global platelet rich plasma & stem cell alopecia treatment market is projected to expand, owing to a rise in the incidence of alopecia and technological advancements.

Rise in Awareness about Platelet Rich Plasma Therapies and Stem Cell Therapies is Propelling the Global Alopecia Treatment Market

The global platelet rich plasma & stem cell alopecia treatment market is expanding at a high growth rate, driven by an increase in awareness about platelet rich plasma & stem cell therapies for treating many types of alopecia. The prevalence of various types of hair loss is increasing rapidly across the world, due to a rise in the geriatric population, anxiety, vaccination, side effects of drugs, etc.. A rise in the incidence of autoimmune hair loss disorders such as alopecia is boosting the platelet rich plasma & stem cell alopecia treatment market.

Request a PDF Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=55800

According to a report in the International Journal of Endocrinology and Metabolism, 2013, female pattern hair loss (FPHL), which is also known as female androgenetic alopecia, is a common condition afflicting millions of women across the world.

Increase in Funding for Alopecia Treatment Research and Stem Cell Research

Stem cells hold promise for the treatment and cure of more than 70 major diseases, including alopecia and other conditions that affect millions of people worldwide. Several private and government organizations are supporting funding for stem cell research. According to Change.org, Inc., in the U.S., 64% of people support federal funding of research on the treatment of chronic diseases using stem cells taken from human embryos. Internationally, stem cell research is supported by significant government investments, with Asia being one of the most favorable regions. Stem cell research funding by the National Institutes of Health (NIH) has increased 17% from US$ 1.2 Bn in 2013 to US$ 1.5 Bn in 2016. In 2017, nonprofit organization Alopecia UK donated US$ 0.6 Mn to the University of the West of Scotland for the development of early treatment to prevent the progression of alopecia areata. Research conducted by the university aims at developing a treatment for alopecia areata using a nonchemical stem-cell based technology based on nanovibrations known as nanokicking.

Request for Analysis of COVID19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=55800

North America Dominates the Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market owing to a Rise in Technological Advancements and Prevalence of Alopecia

North America dominates the global platelet rich plasma & stem cell alopecia treatment market, owing to technological advancements, investments in research & development, and developed health care infrastructure. As per research, in 2015, 21% of women suffered from alopecia in the U.S, which supports the fact that alopecia has a higher prevalence in the country. Moreover, development of innovative products and increase in demand for products among the population in the region are contributing factors for the dominance of North America in the platelet rich plasma & stem cell alopecia treatment market.

Expansion in the Contract Research Industry Offers Significant Opportunities for Companies to Invest in Clinical Trials for Alopecia Treatment

Small and large biopharmaceutical companies have become increasingly reliant on contract research organizations (CRO) and other clinical services specialists to provide research services for their R&D operations. There are numerous government-funded medical and pharmaceutical institutions, with state-of the-art facilities, that can serve as ideal centers for multicentered clinical trials. Companies are expanding their footprints in developing countries, mainly in Asia Pacific. R&D costs in India are substantially lower as compared to those in developed countries. It is possible to conduct both new drug discovery research and novel drug delivery system programs at competitive rates. India offers cost efficiency, as the cost of conducting a trial in the country is 50% to 75% lower compared to that in the U.S. or the European Union.

Purchase Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=55800&ltype=S

Investments, Mergers & Acquisitions, and PARTNERSHIPS by Key Players are Driving the Platelet Rich Plasma & Stem Cell Alopecia Treatment Market

Key players dominating the global platelet rich plasma & stem cell alopecia treatment market are Kerastem, Eclipse, Regen Lab SA, STEMCELL Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy. Major players are focusing on mergers and acquisitions and are investing in the development of platelet rich plasma & stem cell alopecia treatment and making them available to the patient population. For instance, companies such as Stemcell technologies, Inc. highly focus on partnerships with research institutes to develop new advanced products. In 2019, Kerastem signed a partnership agreement with Myungmoon Bio Co., Ltd., a South Korea-based health care company focused on bringing innovative regenerative therapies.

More Trending Reports by Transparency Market Research

Pregnancy Detection Kits Market: https://www.biospace.com/article/pregnancy-detection-kits-market-swot-analysis-of-major-industry-segments/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read the original here:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is Expected to Reach a Value of Approximately US$ 450.5 Mn by the End of 2026 - Science...

Hair Transplant Market – Rise in the Incidences of Alopecia to Bolster Demand in the Market – BioSpace

By Stell Cell Research

The global hair transplant market is forecasted to be driven by the growing number of people suffering from hair loss or hair thinning problem. An emerging pattern of baldness amongst both women and men has augmented the demand for hair transplant surgery in the last few years.

Transplantation of hair refers to a surgical procedure comprising removal of hair follicles from the donor site and then planting it in the balding area of the head. Rising incidences of various causative factors like stress, hormonal imbalance, stress, and augmented fixation about ones physical appearance is likely to boost the global hair transplant market.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6225

The global hair transplant market has been segmented based on market, method, product, therapy, gender, service provider, and region. The main objective of providing such a comprehensive report is to provide a deep insight into the market.

Global Hair Transplant Market: Notable Developments

The global hair transplant market is witness to many developments in the field in the last few years. These market developments indicate a trend in the global hair transplant market. One such development of the market is mentioned below:

Some of the key market players of the global hair transplant market are

Global Hair Transplant Market: Growth Drivers

Rise in the Incidences of Alopecia to Bolster Demand in the Market

Hair transplant has come up as a popular way or solution for hair thinning and balding problems. It has garnered commercial interest as well. According to the findings of California-based National Alopecia Areata Foundation, nearly 6.8 millionpeoplein the US and around 147 million people worldwide already suffer from alopeciaareata or will suffer from the same at some point of time in their lives. The global hair transplant market is likely to grow rapidly on the back of the rising incidences of alopecia. The medical term for hair thinning or balding is called alopecia.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6225&ltype=S

In addition to stress, other factors that cause these problems are deterioration in the quality of water, genetics, illness, side effects of certain medications, and aging. As the number of people suffering from alopecia rises, the scope for the global hair transplant market is likely to widen over the tenure of assessment. In addition, growing fixation over physical appearance is another factor that is estimated to encourage the growth of global hair transplant market in forthcoming years.

Global Hair Transplant Market: Regional Outlook

The global hair transplant market is split into the leading regions of North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Considering geographical segmentation, it is estimated North America is likely dominate the market in the years to come. Increased media and celebrity influence together with augmented awareness about ones physical appearance is likely to encourage growth of the market over the tenure of assessment.

North America hair transplant market is also driven by the high income of the people in the region, which makes hair transplant an affordable solution for hair thinning and balding.

The global hair transplant market is segmented as:

By Market

By Method

By Product

By Therapy

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6225

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Go here to read the rest:
Hair Transplant Market - Rise in the Incidences of Alopecia to Bolster Demand in the Market - BioSpace

Global Stem Cells Market Disclosing Latest Technology Advancement, Global Share, Rising Application Opportunities by Types and Trends 2027 – Scientect

By Induced Pluripotent Stem Cells

A comprehensive research report namelyGlobal Stem Cells Market which discloses an all-encompassing breakdown of the global industry by delivering detailed information about Forthcoming Trends. The Stem Cells Market report delivers an exhaustive analysis of global market size, segmentation market growth, market share, competitive Landscape also an in-depth study of the market enlightening key forecast to 2027, recent developments, opportunities analysis, strategic market growth analysis, and technological innovations.

Get Free Exclusive Sample of this Premium Report at:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-stem-cells-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66377#request_sample

Major Companies Profiled in This Stem Cells Market Report:

Neuralstem, Inc. Stempeutics Research Pvt. Ltd. Reneuron Group Plc Mesoblast Neostem Oncology, Llc Pluristem Therapeutics Inc. Stemcells, Inc. Gamida Cell Ltd. Anterogen Co., Ltd. Orthocyte Corporation Pharmicell Co., Ltd. Apceth GmbHCompany KG Ocata Therapeutics, Inc. U.S. Stem Cell, Inc. (Bioheart) Medipost Co., Ltd. Biotime, Inc. Cell Cure Neurosciences Ltd.

Stem Cells Market report Segmentation: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. This report similarly reduces the current, past, and upcoming market business strategies, estimation analysis having a place with the forecast conditions.

Grab Your Report at an Impressive Discount! Please click here:

https://www.reportspedia.com/discount_inquiry/discount/66377

This all-inclusive study covers an overview of various aspects of the industry including outlook, current Stem Cells Market trends, and advance during the forecast period. Along with this, an in-depth analysis of each section of the report is also provided in the report that consists of the strategies adopted by the key players, challenges, and threats as well as advancements in the industry.

Stem Cells Market Segmentation by Type:

Adult Stem Cell Human Embryonic Stem Cell Induced Pluripotent Stem Cell Rat Neural Stem Cell Other

Based on End Users/Application, the Stem Cells Market has been segmented into:

Drug Discovery and Development Stem Cells Regenerative Medicine

Years Considered to Estimate the Stem Cells Market Size:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2020-2027

Do Make an inquiry of Stem Cells Market Research [emailprotected] https://www.reportspedia.com/report/life-sciences/2015-2027-global-stem-cells-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66377#inquiry_before_buying

Report Answers Following Questions:

Major Point of TOC:

Get a Full Table of [emailprotected] https://www.reportspedia.com/report/life-sciences/2015-2027-global-stem-cells-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66377#table_of_contents

Read more here:
Global Stem Cells Market Disclosing Latest Technology Advancement, Global Share, Rising Application Opportunities by Types and Trends 2027 - Scientect

3D Cell Cultures Industry Report 2020-2025: Impact of COVID-19 on the World of Cell Culture – PRNewswire

By Induced Pluripotent Stem Cells

DUBLIN, Aug. 19, 2020 /PRNewswire/ -- The "3D Cell Cultures: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The report includes:

Whether the discussion is about stem cells, tissue engineering, or microphysiological systems, their vital role in drug discovery, toxicology, and other areas leading to new product development, 3D cell culture is becoming the environment that will increasingly define the basis for future advances.

To mix metaphors, 3D cell culture is also cross-roads through which just about everything else passes on its way to building knowledgebases or introducing new products. This study is needed to bring together and make sense out of the broad body of information encompassed by 3D cell culture.

Three-dimensional cell culture has been used by researchers for many years now, with early adoption and now key roles in cancer and stem cells. Organ-on-a-chip technology, also known as microphysiological systems, is leading to dramatic breakthroughs. Also, stem cell research coupled with synthetic biology is opening new areas. This study is needed to provide a perspective on these advances.

Furthermore, classical toxicology testing programs have been in place for many decades, and over the past 20 years, animal welfare and scientific activities have spurred the development of in vitro testing methods. In silico methods are advancing in novel ways that need to be analyzed and considered in terms of their impacts on cell culture.

This report investigates the recent key technical advances in 3D cell culture equipment, raw materials, assay kits, analytical methods, and clinical research organization (CRO) services. It should also be pointed out that this report takes a somewhat different position on 2D cell culture. It has been criticized for its inadequacies and the misleading information it can produce. However, a review of industry practices makes it clear that it still has its place and will contribute to future advances in unexpected ways.

The company section looks at many of the suppliers who provide equipment, assays, cells, reagents, and services used in 3D cell culture. This study sought to understand business models and market maturity dynamics in greater depth as well as providing more quantitative analysis of their operations.

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary

Chapter 3 Highlights and Issues

Chapter 4 Tissue and Cell Culture: Technology and Product Background

Chapter 5 Assays, Imaging and Analysis

Chapter 6 Regulation and Standardization

Chapter 7 3D Models for Cancer

Chapter 8 Landscape for Toxicology and Drug Safety Testing

Chapter 9 Stem Cell Landscape

Chapter 10 Regenerative Medicine: Organ Transplants and Skin Substitutes

Chapter 11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/jesu26

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more:
3D Cell Cultures Industry Report 2020-2025: Impact of COVID-19 on the World of Cell Culture - PRNewswire

Combating COVID-19 with Cell-Free Expression – The Scientist

By Induced Pluripotent Stem Cells

Imagine the ability to rewire, reshape, and use parts of a living system to build something new. It is not science fiction, nor is it Frankensteins monster. It is synthetic biology, a relatively nascent field that is making a profound impact on society and healthcare. As the world continues to grapple with the ongoing effects of the COVID-19 pandemic, researchers are turning to synthetic biology, and in particular, to cell-free expression systems to develop new rapid diagnostic tools, vaccines, and treatments.

Its a way to program information. We all do that every day in our cell phones; we program information in zeros and ones. Synthetic biology takes that to a totally new dimension. Rather than just being able to control information, I now get to control information that builds atoms, said Michael Jewett, a professor of chemical and biological engineering at Northwestern University.

Synthetic biologists such as Jewett combine engineering principles, computer programming, and molecular biology to design and build synthetic gene circuits and other molecular components that rewire living cells for a variety of new applications, including biological sensors and diagnostic tests.

Going Cell-Free

Rewiring a living system is tricky. Cells are already biologically programmed to achieve their own functional goals, not the goals of the researcher. To circumvent this problem, synthetic biologists remove the cell wall and extract the cells molecular machinery, including the core factors needed for transcription and translation. This cell-free expression system can then be coerced to produce and even detect proteins of interest.

It's like if you took a car, you lift up the hood, pull out the engine, and you repurpose it for something else. We're repurposing the molecular machinery to do some objective function, said Jewett. Working outside a cellular system prevents the cell from responding and changing its gene expression profile, ensuring a reproducible and stable molecular expression system.

The complexities itself are much lower than that of the living cells, and it's easier to control the different features in that you can dictate, at least at the outset, what [compounds] are there and how much is there, said James Collins a professor of biological engineering at the Massachusetts Institute of Technology.

Scientists have used cell-free expression systems for two decades as a basic research tool to make discoveries about the living world. In fact, scientists used cell-free systems to uncover the genetic code in the 1960s. However, many of these early systems were small-scale, did not last very long, and could not make complex proteins. Within the last 20 years, researchers have addressed each of these problems, transforming cell-free expression systems from a basic tool into a useable technology platform.

The systems now, instead of lasting five minutes, last 15 to 20 hours in batch reactions. They can make really complex proteins all the way up to full-length antibodies, which are used in medicine. They can carry out pretty complex integrated circuitry that can basically detect, sense, and respond to something just like a cell, said Jewett.

Researchers also developed better ways to support cell-free expression systems by supplying the system with glucose as a source of energy and other biological compounds such as amino acids needed to produce proteins. Scientists even solved the problem of scalability. If you imagine running a PCR reaction, which is typically two or five microliters, in a 1000-liter scale, that's what we're doing economically, which is crazy. In fact, many people kind of deemed that impossible 10 years ago, but it's happening, said Jewett.

Cell-free expression systems can be rapidly pre-assembled and stored in a laboratory freezer, or freeze-dried in a powdered form. This eliminates the need for researchers to regrow cells. The problems then reduce to automated liquid handling, said Jewett. Automated liquid handling robots enable researchers to run more samples at a time for rapid library screening or analyzing genetic parts and gene circuits.

Making cell-free expression systems is an art that, much like any other laboratory technique, takes skill, practice, and time. Some researchers make their own cell-free expression systems, but others purchase commercial ready-to-use master mixes. These mixes, such as the myTXTL Cell-Free Expression System from Arbor Biosciences, come pre-loaded with all the molecular components for a given reaction so that the researcher only has to add their DNA sample for reliable and robust high-yield protein expression.

The homebrew has some really nice efforts by Michael Jewett and his team to get them highly functional, but when we make our own, we're not as good and so it often doesnt have the functionality level that we need, said Collins. My team has used Arbor Biosciences; they have very good products. In the cell-free world, they're one of the go-to [companies]. Like homebrewed systems, purchased premixed cell-free systems can also be paired with automated liquid handling for high-throughput and efficient library screening or analysis.

Pivoting

These advances made it possible for synthetic biologists to develop practical technologies that mitigate disease and impact society. When the COVID-19 pandemic struck, synthetic biologists pivoted the cell-free expression technology that they were using for other diseases to develop new diagnostics, materials, and treatments specifically for COVID-19.

Keith Pardee, a synthetic biologist at the University of Toronto was working on a three-year project to send Zika virus diagnostic testing kits to low- and middle-income countries. When the COVID-19 outbreak happened, we thought this is obviously a natural thing for us to do. So, we basically are taking that platform for Zika and applying it to SARS-CoV-2, said Pardee.

Pardee extracts enzymes needed for transcription and translation from Escherichia coli to create a cell-free expression system that senses parts of the SARS-CoV-2 genome and triggers a molecular switch to produce a reporter protein. It also eliminates the need to purify RNA from the sample and can replace RT-PCR for more rapid diagnostic testing. Because we didnt have that black box of working with a cell, we were able to get sensors very quickly, maybe within two days of having the synthetic DNA arrive in the lab, we had sensors working, said Pardee.

Pardee will send COVID-19 diagnostic kits in two waves to the same countries that he was planning to send the Zika kits, only now he has added Toronto, Canada to the list. The first wave will supply 1000 test kits a day for two weeks. The second wave will contain a lab-in-a-box, that could convert a common microbiology lab into a diagnostic testing lab to maintain a sustained testing capacity.

Similarly, James Collins was developing a suite of clothing-based sensors for healthcare workers, first responders, and military personnel to detect the presence of viruses or compounds. The idea would be like a lab coat of the future, said Collins. He conceived the idea during the Ebola outbreak of 2014. Collins and his team freeze-dried cell-free expression systems and locked them onto a piece of paper, and later into fabric. They then showed that the system could be rehydrated and transcription and translation activated by adding liquid.

We were revising this publication when the pandemic hit, and realized that we could embody the same technology into facemasks by having an insert that can be added. If a person is infected, they'll give out particles in water vaporthat is coughing, sneezing, talkingand that itself could activate these freeze-dried components, said Collins. If a person were infected, the mask would produce a fluorescent signal that could be detected using a handheld fluorometer.

Collinss previous discoveries in synthetic biology also contributed to the technology behind the Moderna vaccine for COVID-19, which is in the late-stages of development. Ten years ago, with George Daly and Derek Rossi, Collins developed a stable synthetic mRNA system to express proteins directly in cells. They used the technology to efficiently reprogram induced pluripotent stem cells, but mentioned in the paper that the technology could be used for RNA-based vaccine development.

I've been so motivated by so many scientists, by how much we're all redirecting; we're pivoting, said Jewett. Four months ago, Jewetts research focused primarily on developing water-based diagnostics for identifying toxins. Using the same cell-free expression approaches, Jewett is now developing CRISPR-based diagnostics for rapid COVID-19 detection and working on antiviral frontline approaches to stop COVID-19 infection.

Using cell-free expression systems, Jewetts team identifies proteins that could cloak the COVID-19 spike protein and prevent its connection to cell receptors. Identifying good clones using classic mammalian cell-culture can take 12 -18 months. We need two months. We need four weeks. We need to have technologies that can meet the pace of this pandemic, said Jewett. Instead of growing cells, Jewett and his team thaw pre-built, frozen cell-free expression stocks, add DNA, and identify good candidates within a day.

If other laboratories are interested in pivoting but are unable to pre-assemble frozen stocks or lack the technical experience needed, they can reach out to commercial providers, such as Arbor Biosciences for reliable cell-free expression systems. Arbor Biosciences is adept at developing robust cell-free systems that can be immediately implemented in COVID-19 research or in other disease-based research for rapid, efficient, and dependable discovery.

In this era of emergent and reemerging pandemic outbreaks, what we need is speed. Cell-free systems really offer this exciting component, and the technology is well suited to address that need, said Jewett. Cell-free expression systems alone will not solve the COVID-19 pandemic, but it can complement existing technologies. Research is just developing. We, like many others, have been conceiving ideas and schemes and now's the time, said Jewett. We have to make an impact with whatever we can.

Meet the Sponsor

Arbor Biosciences is a development and manufacturing company founded by scientists to serve our peers in molecular biology applications.

Read more here:
Combating COVID-19 with Cell-Free Expression - The Scientist

Study sheds light on why retinal ganglion cells are vulnerable to glaucoma – Jill Lopez

By Stem Cell Medical Center

Millions of sufferers of glaucoma might someday benefit from a study released today inSTEM CELLSin which a "disease in a dish" stem cell model was used to examine the mechanism in glaucoma that causes retinal ganglion cells (RGCs) to degenerate, resulting in loss of vision. The knowledge the study provides could result in new therapeutic approaches for this leading cause of blindness worldwide.

RGCs are a group of nerve cells located in the retina that send images to the brain and enable you to see. Glaucoma attacks these cells and, once they die, they are not replaced. However, why and how glaucoma causes the RGCs to degenerate is something of a mystery.

Stem cell modeling of the disease may shed light on this. Over the past decade, significant progress has been made using induced pluripotent stem cell (iPSC) technology to mimic glaucoma. This includes the generation of human RGCs from iPSCs, which led to the development of a disease model for primary open angle glaucoma (POAG) -- the most common form of glaucoma -- as well as an optic nerve model that demonstrated the supportive role of mTOR signaling in the regeneration of hRGC axons following chemical axotomy.

"However, both these models can be improved by characterizing the developmental trajectories of control and disease-specific RGCs," said Iqbal Ahmad, Ph.D., of the University of Nebraska Medical Center. He and his UNMC colleagues, Pooja Teotia, Ph.D., and Meng Niu, Ph.D., conducted the study reported on inSTEM CELLS.

Dr. Ahmad continued, "This characterization includes the generation of hRGCs through normal developmental time and stages containing a complement of different subtypes, against which the developmental aspects of RGC abnormality in a disease model can be evaluated. Information about different RGC subtypes is not only important from a functional viewpoint, but also for understanding the underlying mechanism of glaucomatous degeneration, given the emerging evidence that the susceptibility and resistance of RGCs are subtype dependent."

In developing their model, the researchers used a single cell transcriptome analysis of human RGCs generated from normal (controls) and SIX6 risk allele iPS cells. (Previous studies have identified a significant association between POAG and SIX6, a gene that plays a role in ocular development.)

They observed that the developmental trajectories, beginning from neural stem cells to RGCs, were similar between SIX6 risk allele and control RGCs.

"However," Dr. Ahmad said, "we observed that the differentiation of SIX6 risk allele RGCs was stalled at the retinal progenitor cell stage, keeping them immature and deficient in subtype composition, compared to the controls. This was likely due to dysregulated mTOR and Notch signaling pathways that play an important role in RGC development. Furthermore," he added, "SIX6 risk allele RGCs, as compared to controls, expressed fewer genes corresponding to RGC subtypes that are preferentially resistant to degeneration.

"The immature phenotype of SIX6 risk allele RGCs with under-represented degeneration-resistant subtypes, may make them vulnerable to glaucomatous degeneration," he concluded.

"This study demonstrates the power of single cell sequencing methods for providing new insights into POAG pathology at the cellular and molecular level, which is necessary for formulation of new therapeutic approaches", said Dr. Jan Nolta, Editor-in-Chief ofSTEM CELLS. "This is truly remarkable and something that we could have not imagined was feasible thirteen years ago until the concept of patient specific iPSC disease modelling was invented. This is an excellent step forward and a phenomenon we will see becoming a daily reality in disease phenotyping and drug discovery."

View original post here:
Study sheds light on why retinal ganglion cells are vulnerable to glaucoma - Jill Lopez

Israel and UAE team up on stem cell therapy research for COVID-19 – UPI News

By Stem Cell Treatment

David Adom wears protective clothing while working in a coronavirus drive through tent in Jerusalem. On Monday, Israel and United Arab Emirates stem cell companies announced collaboration on research on COVID-19 treatments. Photo by Debbie Hill/UPI | License Photo

Aug. 17 (UPI) -- Israel and United Arab Emirates stem cell therapy companies signed an agreement Monday to collaborate on researching potential treatment for COVID-19.

The accord between Israel's Pluristem Therapeutics and UAE's Abu Dhabi Stem Cells Center aims to capitalize on each company's expertise to develop therapies and regenerative medicines for the treatment of severe diseases including COVID-19, according to a joint statement.

Both companies have been treating COVID-19 patients with stem cells.

Pluristem has been treating COVID-19 patients with a placenta-based stem cell therapy. The U.S. Food and Drug Administration cleared the Israel stem cell therapy company in May for a Phase II study of the treatment for severe COVID-19 cases. Preliminary results released in May from compassionate-use programs in Israel and the United States were promising, showing that 75 percent of participants no longer needed mechanical ventilation within 28 days.

The Abu Dhabi Stem Cells Center has started a therapy that returns blood-based stem cells back into the patient's lungs as a fine mist through a nebulizer.

"We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that we believe will advance healthcare within and across our borders," Pluristem CEO and President Yaky Yanay said in the statement.

The ADSCC's General Manager Dr. Yendry Ventura also commented on the deal in the statement.

"Pluristem is a major player in the cell therapy field with years of experience, a unique platform and robust clinical pipeline," Ventura said. "We are excited to join forces and to promote the research and development of cell therapies for the best of the patients and the human society as a whole."

The deal is the second cross-border agreement since President Donald Trump brokered a deal to normalize ties between Israel and the UAE. It follows a cross-border deal on Sunday between UAE-based APEX National Investment and Israel's TeraGroup to conduct research on the coronavirus.

World News // 21 minutes ago

South Korea official proposes changes to U.S. working group

Aug. 18 (UPI) -- South Korea's newly appointed unification chief proposed "readjustments" to a bilateral working-level group with the United States, during a meeting with the top U.S. envoy in Seoul.

World News // 3 hours ago

6.6-magnitude earthquake strikes Philippines; 1 dead

Aug. 18 (UPI) -- A 6.6-magnitude earthquake struck central Philippines Tuesday, killing at least one person, officials said.

World News // 14 hours ago

Toronto police agree to $12.5M settlement for mass arrests at G-20

Aug. 17 (UPI) -- Ten years after mass-arrests in Toronto at the 2010 G-20 economic summit, the Toronto Police Services Board will pay a $12.5 million settlement to members of a class-action lawsuit of 1,100 people who were detained.

World News // 19 hours ago

Spanish Royal Household confirms former king Juan Carlos I is in UAE

Aug. 17 (UPI) -- Spain's Royal Household confirmed Monday that emeritus king, Juan Carlos I, is in United Arab Emirates after uncertainty since he went into exile two weeks ago amid financial scandals.

World News // 19 hours ago

China has new weapon to target airfields, state media says

Aug. 17 (UPI) -- Beijing's military has developed a hybrid weapon capable of destroying an entire airfield with one hit, according to Chinese state media on Monday.

World News // 20 hours ago

South Korea police to handle spy cases, report says

Aug. 17 (UPI) -- Seoul's National Police Agency will take control over all investigations into anti-state espionage previously conducted by the National Intelligence Service.

World News // 22 hours ago

BTS music label worth $2.5B ahead of IPO, report says

Aug. 17 (UPI) -- The South Korean label that manages boy band BTS is expected to make an initial public offering after passing a preliminary screening, according to a South Korean press report.

World News // 22 hours ago

Ryanair cuts capacity for next 2 months due to restrictions

Aug. 17 (UPI) -- Irish carrier Ryanair announced Monday it will reduce flight capacity by 20% in September and October, due to European travel restrictions.

World News // 23 hours ago

North Korea quiet as U.S., South Korea exercises to resume

Aug. 17 (UPI) -- North Korea is keeping silent ahead of U.S.-South Korea military exercises this week.

World News // 23 hours ago

German regulators investigate Amazon pricing policies

Aug. 17 (UPI) -- Antitrust regulators in Germany are investigating complaints that Amazon is unfairly leveraging its dominant position in the e-commerce market to affect pricing during the coronavirus pandemic.

Excerpt from:
Israel and UAE team up on stem cell therapy research for COVID-19 - UPI News

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs – GlobeNewswire

By Stem Cell Treatment

August 18, 2020 07:00 ET | Source: https://immatics.com/

multilang-release

Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) --

Tuebingen, Germany and Houston, Texas, August 18, 2020 Immatics N.V. (NASDAQ: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the treatment of the first patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by FDA) approval by Paul-Ehrlich-Institute (PEI), the regulatory body for cell and gene therapies in Germany. In addition, Immatics has been granted regulatory approval by PEI to initiate another phase I clinical trial in Germany to evaluate safety, tolerability and initial signs of clinical efficacy of IMA203.

The clinical trials of the IMA200 series will investigate up to three novel cancer immunotherapies, which include IMA202 (NCT03441100) and IMA203 (NCT03686124). IMA202 and IMA203 are designed to target unique peptides derived from either melanoma-associated antigen 1 (MAGEA1) or preferentially expressed antigen in melanoma (PRAME), respectively. Both are built on Immatics proprietary ACTengine approach in which the patients own T cells are genetically engineered to express an exogenous T cell receptor (TCR) directed against true cancer targets. By introducing this novel cancer specific TCR, the goal is to redirect and selectively activate the patients T cells to fight the tumor. The studies will investigate the safety and tolerability of Immatics Adoptive Cell Therapies (ACT) in patients with target-positive solid cancers and seek initial signals of anti-tumor activity. Moreover, persistence of the infused engineered T cells will be monitored in the patients blood as T cell persistence is considered a major pre-requisite to obtain an anti-tumor response. The aim is to develop innovative personalized immunotherapies targeting a patients tumor selectively and effectively.

The initial group of clinical trial sites in Germany includes the University Hospital Carl Gustav Carus in Dresden, the University Hospital Bonn and the University Hospital of Wrzburg. Previous patients in the IMA200 series were initially enrolled at The University of Texas MD Anderson Cancer Center in Houston, Texas, and more recently at the Columbia University Irving Medical Center in New York and the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania.

Cedrik Britten, MD, Chief Medical Officer of Immatics commented: As part of our strategy to increase the geographical foot-print for our clinical sites, we are currently expanding them in the US and in Europe. We are delighted to have gained a new regulatory approval from PEI and to have treated the first patient in Germany. This expansion elevates our clinical organization to a global level and adds operational flexibility that has become even more important in light of the global COVID-19 pandemic. We look forward to continuing to collaborate with leading clinicians to advance our mission of delivering the power of T cells to cancer patients on both sides of the Atlantic.

Dr. Martin Wermke, Coordinating Investigator and Head of the Early Clinical Trial Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany, commented: Having been involved since the early stages of this clinical research, I am excited to witness the next phase of development of this fascinating pipeline of immunotherapies. I am confident that Immatics innovative T cell therapies hold the potential to alter the future therapeutic landscape of solid and hematologic malignancies.

Additional information about the clinical studies is available at http://www.immatics.com/clinical-programs/ and http://www.clinicaltrials.gov.

About Immatics Adoptive Cell Therapies Adoptive Cell Therapy (ACT) is a therapeutic approach that uses natural or engineered T cells to fight cancer. Immatics has developed three innovative, proprietary approaches to produce Adoptive Cell Therapies: ACTengine, off-the-shelf ACTallo and the multi-target pilot trial ACTolog.

About ACTengine Immatics clinical product class ACTengine is a personalized approach for patients with advanced solid cancers. Patients own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics cancer targets identified by its proprietary XPRESIDENT target discovery platform.

About the ACTengine clinical trials (IMA201, IMA202 and IMA203)

Patient receiving an investigational therapy based on Immatics ACTengine approach.

Notes to Editors

About Immatics Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics pipeline consists of two distinct therapeutic modalities of Adoptive Cell Therapies and TCR Bispecifics. Adoptive Cell Therapy programs are developed in collaboration through Immatics US with The University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). The ACT T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Twitter and LinkedIn.

Forward-Looking Statements: Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Follow this link:
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs - GlobeNewswire

→←